Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2022. The key information is detailed in the press release furnished as Exhibit 99.1, which provides the company's performance metrics for the period. Investors should review the press release for specific details on revenue, earnings, and any forward-looking statements or business developments announced. This filing serves as the official notification of the quarterly results and is crucial for understanding the company's recent financial standing and operational achievements.
Key Highlights
- 1Filing of Form 8-K on November 3, 2022, announcing third quarter 2022 financial and operating results.
- 2The press release detailing these results is included as Exhibit 99.1.
- 3Information furnished is not considered 'filed' for Section 18 purposes unless expressly incorporated by reference in other filings.
- 4Provides investors with the official third-quarter financial and operational performance data.
- 5Incorporates by reference the press release dated November 3, 2022.